CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon.
Laubach JP et al. Clin Cancer Res. 2015 Apr 15. pii: clincanres.3190.2015. [Epub ahead of print].

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ et al. Front Pharmacol. 2015 Mar 31;6:70. doi: 10.3389/fphar.2015.00070. eCollection 2015.

Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
Zhu J et al. Drug Discov Today. 2015 Apr 6. pii: S1359-6446(15)00119-1. doi: 10.1016/j.drudis.2015.03.009. [Epub ahead of print].

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG et al. Future Oncol. 2015 Apr;11(8):1153-68. doi: 10.2217/fon.15.9.